Trade Adverum Biotechn - ADVM CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0150 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Adverum Biotechnologies Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 0.8055 |
| Open* | 0.8076 |
| 1-Year Change* | 22.94% |
| Day's Range* | 0.7855 - 0.8817 |
| 52 wk Range | 0.53-2.34 |
| Average Volume (10 days) | 178.78K |
| Average Volume (3 months) | 4.95M |
| Market Cap | 86.88M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 101.03M |
| Revenue | 3.60M |
| EPS | -1.26 |
| Dividend (Yield %) | N/A |
| Beta | 0.75 |
| Next Earnings Date | Mar 28, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | 0.8055 | 0.0050 | 0.62% | 0.8005 | 0.8087 | 0.7755 |
| Nov 30, 2023 | 0.8042 | -0.0063 | -0.78% | 0.8105 | 0.8186 | 0.7955 |
| Nov 29, 2023 | 0.8155 | 0.0000 | 0.00% | 0.8155 | 0.8255 | 0.8100 |
| Nov 28, 2023 | 0.8105 | -0.0355 | -4.20% | 0.8460 | 0.8465 | 0.8015 |
| Nov 27, 2023 | 0.8456 | -0.0369 | -4.18% | 0.8825 | 0.8825 | 0.8361 |
| Nov 24, 2023 | 0.8751 | 0.0496 | 6.01% | 0.8255 | 0.8751 | 0.8255 |
| Nov 22, 2023 | 0.8357 | -0.0298 | -3.44% | 0.8655 | 0.8855 | 0.8255 |
| Nov 21, 2023 | 0.8555 | -0.0401 | -4.48% | 0.8956 | 0.8956 | 0.8555 |
| Nov 20, 2023 | 0.9093 | 0.0238 | 2.69% | 0.8855 | 0.9186 | 0.8655 |
| Nov 17, 2023 | 0.8955 | 0.0300 | 3.47% | 0.8655 | 0.8972 | 0.8455 |
| Nov 16, 2023 | 0.8755 | 0.0394 | 4.71% | 0.8361 | 0.8850 | 0.8361 |
| Nov 15, 2023 | 0.8756 | 0.0401 | 4.80% | 0.8355 | 0.8756 | 0.8255 |
| Nov 14, 2023 | 0.8566 | -0.0089 | -1.03% | 0.8655 | 0.8956 | 0.8455 |
| Nov 13, 2023 | 0.8955 | -0.0300 | -3.24% | 0.9255 | 0.9255 | 0.8355 |
| Nov 10, 2023 | 0.9055 | 0.0200 | 2.26% | 0.8855 | 0.9234 | 0.8782 |
| Nov 9, 2023 | 0.8956 | 0.0001 | 0.01% | 0.8955 | 0.9128 | 0.8674 |
| Nov 8, 2023 | 0.8955 | 0.0000 | 0.00% | 0.8955 | 0.9510 | 0.8701 |
| Nov 7, 2023 | 0.9055 | -0.0600 | -6.21% | 0.9655 | 0.9655 | 0.8935 |
| Nov 6, 2023 | 0.9455 | -0.1500 | -13.69% | 1.0955 | 1.0955 | 0.9455 |
| Nov 3, 2023 | 0.9267 | -0.0688 | -6.91% | 0.9955 | 0.9955 | 0.9267 |
Adverum Biotechn Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, March 28, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Adverum Biotechnologies Inc Earnings Release Q4 2023 Adverum Biotechnologies Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 7.5 | 0 | 0.25 | 1.612 |
| Revenue | 0 | 7.5 | 0 | 0.25 | 1.612 |
| Total Operating Expense | 157.135 | 153.622 | 117.95 | 68.795 | 79.693 |
| Selling/General/Admin. Expenses, Total | 55.758 | 63.341 | 44.641 | 28.376 | 24.56 |
| Research & Development | 99.277 | 89.181 | 73.309 | 40.419 | 50.133 |
| Unusual Expense (Income) | 2.1 | 1.1 | 0 | 5 | |
| Operating Income | -157.135 | -146.122 | -117.95 | -68.545 | -78.081 |
| Interest Income (Expense), Net Non-Operating | |||||
| Other, Net | 2.673 | 0.582 | 1.557 | 4.059 | 4.204 |
| Net Income Before Taxes | -154.462 | -145.54 | -116.393 | -64.486 | -73.877 |
| Net Income After Taxes | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Net Income Before Extra. Items | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Net Income | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Income Available to Common Excl. Extra. Items | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Income Available to Common Incl. Extra. Items | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Diluted Net Income | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Diluted Weighted Average Shares | 99.251 | 98.039 | 85.146 | 64.102 | 61.375 |
| Diluted EPS Excluding Extraordinary Items | -1.55702 | -1.48451 | -1.38006 | -1.00599 | -1.18333 |
| Diluted Normalized EPS | -1.54327 | -1.47329 | -1.38006 | -1.00599 | -1.13038 |
| Total Extraordinary Items |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 3.6 | 0 | 0 | 0 |
| Revenue | 0 | 3.6 | 0 | 0 | 0 |
| Total Operating Expense | 33.065 | 33.839 | 33.94 | 41.037 | 44.025 |
| Selling/General/Admin. Expenses, Total | 12.466 | 12.78 | 9.641 | 17.188 | 13.76 |
| Research & Development | 20.599 | 21.059 | 22.199 | 23.849 | 28.265 |
| Operating Income | -33.065 | -30.239 | -33.94 | -41.037 | -44.025 |
| Other, Net | 1.576 | 1.2 | 1.223 | 0.923 | 0.283 |
| Net Income Before Taxes | -31.489 | -29.039 | -32.717 | -40.114 | -43.742 |
| Net Income After Taxes | -31.51 | -29.056 | -32.736 | -40.131 | -43.761 |
| Net Income Before Extra. Items | -31.51 | -29.056 | -32.736 | -40.131 | -43.761 |
| Net Income | -31.51 | -29.056 | -32.736 | -40.131 | -43.761 |
| Income Available to Common Excl. Extra. Items | -31.51 | -29.056 | -32.736 | -40.131 | -43.761 |
| Income Available to Common Incl. Extra. Items | -31.51 | -29.056 | -32.736 | -40.131 | -43.761 |
| Diluted Net Income | -31.51 | -29.056 | -32.736 | -40.131 | -43.761 |
| Diluted Weighted Average Shares | 100.768 | 100.304 | 99.923 | 99.475 | 99 |
| Diluted EPS Excluding Extraordinary Items | -0.3127 | -0.28968 | -0.32761 | -0.40343 | -0.44203 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.3127 | -0.28968 | -0.31395 | -0.40343 | -0.4289 |
| Unusual Expense (Income) | 2.1 | 0 | 2 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 190.595 | 317.145 | 434.438 | 175.87 | 208.754 |
| Cash and Short Term Investments | 185.589 | 305.188 | 429.729 | 166.035 | 205.079 |
| Cash & Equivalents | 68.431 | 34.195 | 62.424 | 65.897 | 154.949 |
| Total Receivables, Net | 0 | 5.709 | |||
| Prepaid Expenses | 5.006 | 6.248 | 4.709 | 9.835 | 3.675 |
| Total Assets | 308.372 | 439.727 | 482.567 | 222.727 | 213.495 |
| Property/Plant/Equipment, Total - Net | 113.861 | 119.06 | 47.101 | 45.847 | 3.586 |
| Property/Plant/Equipment, Total - Gross | 130.855 | 132.234 | 57.173 | 53.839 | 10.008 |
| Accumulated Depreciation, Total | -16.994 | -13.174 | -10.072 | -7.992 | -6.422 |
| Intangibles, Net | 0 | ||||
| Other Long Term Assets, Total | 3.916 | 2.753 | 1.028 | 1.01 | 1.155 |
| Total Current Liabilities | 32.246 | 21.32 | 20.871 | 19.408 | 10.719 |
| Accounts Payable | 2.238 | 1.387 | 2.81 | 4.103 | 1.707 |
| Accrued Expenses | 29.754 | 18.615 | 18.061 | 15.305 | 8.784 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.254 | 1.318 | 0.228 | ||
| Total Liabilities | 126.854 | 123.542 | 48.22 | 47.77 | 12.328 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | ||||
| Other Liabilities, Total | 94.608 | 102.222 | 27.349 | 28.362 | 1.609 |
| Total Equity | 181.518 | 316.185 | 434.347 | 174.957 | 201.167 |
| Common Stock | 0.01 | 0.01 | 0.01 | 0.007 | 0.006 |
| Additional Paid-In Capital | 985.651 | 964.965 | 937.134 | 560.704 | 522.503 |
| Retained Earnings (Accumulated Deficit) | -802.612 | -648.076 | -502.536 | -385.029 | -320.543 |
| Other Equity, Total | -1.531 | -0.714 | -0.261 | -0.725 | -0.799 |
| Total Liabilities & Shareholders’ Equity | 308.372 | 439.727 | 482.567 | 222.727 | 213.495 |
| Total Common Shares Outstanding | 100.117 | 98.381 | 97.549 | 67.329 | 62.9655 |
| Short Term Investments | 117.158 | 270.993 | 367.305 | 100.138 | 50.13 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Note Receivable - Long Term | 0 | 0.769 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 124.596 | 147.143 | 168.873 | 190.595 | 213.243 |
| Cash and Short Term Investments | 117.082 | 141.453 | 164.285 | 185.589 | 203.264 |
| Cash & Equivalents | 105.366 | 111.187 | 67.552 | 68.431 | 84.43 |
| Short Term Investments | 11.716 | 30.266 | 96.733 | 117.158 | 118.834 |
| Prepaid Expenses | 7.514 | 5.69 | 4.588 | 5.006 | 9.979 |
| Total Assets | 196.77 | 241.429 | 275.577 | 308.372 | 332.362 |
| Property/Plant/Equipment, Total - Net | 68.254 | 90.328 | 102.85 | 113.861 | 116.461 |
| Property/Plant/Equipment, Total - Gross | 81.756 | 110.448 | 121.436 | 130.855 | 133.855 |
| Accumulated Depreciation, Total | -13.502 | -20.12 | -18.586 | -16.994 | -17.394 |
| Other Long Term Assets, Total | 3.92 | 3.958 | 3.854 | 3.916 | 2.658 |
| Total Current Liabilities | 28.856 | 44.518 | 46.472 | 32.246 | 28.621 |
| Accounts Payable | 2.17 | 1.418 | 2.863 | 2.238 | 0.846 |
| Accrued Expenses | 26.584 | 43.029 | 43.345 | 29.754 | 27.474 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 94.056 | 110.274 | 117.82 | 126.854 | 124.025 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 65.2 | 65.756 | 71.348 | 94.608 | 95.404 |
| Total Equity | 102.714 | 131.155 | 157.757 | 181.518 | 208.337 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Additional Paid-In Capital | 999.319 | 994.929 | 990.214 | 985.651 | 980.156 |
| Retained Earnings (Accumulated Deficit) | -896.063 | -863.178 | -831.668 | -802.612 | -769.876 |
| Other Equity, Total | -0.552 | -0.606 | -0.799 | -1.531 | -1.953 |
| Total Liabilities & Shareholders’ Equity | 196.77 | 241.429 | 275.577 | 308.372 | 332.362 |
| Total Common Shares Outstanding | 101.027 | 100.993 | 100.573 | 100.117 | 99.728 |
| Total Receivables, Net | 0 | 0 | |||
| Other Current Liabilities, Total | 0.102 | 0.071 | 0.264 | 0.254 | 0.301 |
| Note Receivable - Long Term | 0 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Cash From Operating Activities | -108.091 | -107.831 | -79.291 | -49.17 | -53.964 |
| Cash From Operating Activities | 6.528 | 4.645 | 4.158 | 1.573 | 1.75 |
| Non-Cash Items | 20.028 | 29.002 | 21.329 | 8.684 | 18.534 |
| Changes in Working Capital | 19.889 | 4.062 | 12.729 | 5.059 | -0.371 |
| Cash From Investing Activities | 141.72 | 78.709 | -280.167 | -68.073 | 69.444 |
| Capital Expenditures | -11.816 | -15.123 | -11.844 | -19.247 | -0.809 |
| Other Investing Cash Flow Items, Total | 153.536 | 93.832 | -268.323 | -48.826 | 70.253 |
| Cash From Financing Activities | 0.607 | 2.397 | 355.985 | 28.191 | 69.949 |
| Financing Cash Flow Items | 0 | -2.043 | -1.47 | -1.191 | |
| Issuance (Retirement) of Stock, Net | 0.607 | 2.637 | 358.089 | 29.773 | 71.215 |
| Issuance (Retirement) of Debt, Net | 0 | -0.24 | -0.061 | -0.112 | -0.075 |
| Foreign Exchange Effects | 0 | ||||
| Net Change in Cash | 34.236 | -26.725 | -3.473 | -89.052 | 85.429 |
| Deferred Taxes | 0 | -1.25 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -29.056 | -154.536 | -121.8 | -81.669 | -37.908 |
| Cash From Operating Activities | -22.412 | -108.091 | -89.616 | -57.808 | -28.929 |
| Cash From Operating Activities | 1.592 | 6.528 | 4.816 | 3.028 | 1.425 |
| Non-Cash Items | 3.622 | 20.028 | 15.135 | 12.617 | 5.501 |
| Changes in Working Capital | 1.43 | 19.889 | 12.233 | 8.216 | 2.053 |
| Cash From Investing Activities | 21.533 | 141.72 | 139.486 | 115.118 | 84.383 |
| Capital Expenditures | -0.085 | -11.816 | -11.631 | -10.807 | -4.374 |
| Other Investing Cash Flow Items, Total | 21.618 | 153.536 | 151.117 | 125.925 | 88.757 |
| Cash From Financing Activities | 0 | 0.607 | 0.365 | 0.365 | 0.003 |
| Financing Cash Flow Items | |||||
| Issuance (Retirement) of Stock, Net | 0 | 0.607 | 0.365 | 0.365 | 0.003 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
| Net Change in Cash | -0.879 | 34.236 | 50.235 | 57.675 | 55.457 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Commodore Capital LP | Hedge Fund | 9.9017 | 10000000 | 3841859 | 2023-06-30 | MED |
| Fidelity Management & Research Company LLC | Investment Advisor | 7.685 | 7761292 | -8532 | 2023-06-30 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 6.893 | 6961467 | -1610 | 2023-06-30 | MED |
| VR Adviser, LLC | Venture Capital | 5.8415 | 5899489 | 2013243 | 2023-07-14 | MED |
| BofA Global Research (US) | Research Firm | 5.5368 | 5591790 | 0 | 2023-06-30 | LOW |
| Versant Ventures | Venture Capital | 5.0184 | 5068233 | 0 | 2023-06-30 | LOW |
| Goldman Sachs & Company, Inc. | Research Firm | 4.5163 | 4561168 | 3509 | 2023-06-30 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.0221 | 4062034 | -81097 | 2023-06-30 | LOW |
| BML Capital Management LLC | Investment Advisor | 3.8765 | 3915000 | -1242179 | 2023-09-30 | HIGH |
| Sonic GP LLC | Hedge Fund | 1.9803 | 2000000 | 0 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.3172 | 1330314 | -336287 | 2023-06-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.2047 | 1216641 | 79900 | 2023-06-30 | HIGH |
| AIGH Capital Management, LLC. | Private Equity | 1.1019 | 1112874 | 211434 | 2023-06-30 | MED |
| Newtyn Management, LLC | Hedge Fund | 0.9902 | 1000000 | -528400 | 2023-06-30 | MED |
| Two Sigma Investments, LP | Hedge Fund | 0.9036 | 912540 | -384567 | 2023-06-30 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8783 | 887046 | 99146 | 2023-06-30 | LOW |
| Fischer (Laurent D M.D.) | Individual Investor | 0.7977 | 805574 | 125433 | 2023-04-01 | LOW |
| Bellecapital Partners AG | Investment Advisor/Hedge Fund | 0.5377 | 543035 | 0 | 2023-02-28 | LOW |
| Quinn Opportunity Partners LLC | Hedge Fund | 0.3944 | 398298 | 0 | 2023-06-30 | HIGH |
| Worth Venture Partners, LLC | Investment Advisor/Hedge Fund | 0.367 | 370683 | 72123 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Adverum Biotechn Company profile
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Adverum Biotechnologies Inc revenues increased from $0K to $7.5M. Net loss increased 39% to $111.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 74% to $37.8M (expense), Research and development -gross increase of 31% to $59.5M (expense).
| Industry: | Bio Therapeutic Drugs |
100 Cardinal Way
REDWOOD CITY
CALIFORNIA 94063
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com